CB vs LCTX · P/E 14, rev $59.40B vs rev $9.5M
Chubb Ltd (CB) versus Lineage Cell Therapeutics Inc (LCTX) — a side-by-side from cached financials, not a winner call.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Lineage Cell Therapeutics Inc (LCTX) is a biotechnology company listed on US.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Latest reported LCTX revenue for 2024-12-31 was $9.5M. Net income was -$18.6M. Revenue was up 354.9% from 2023-12-31 to 2024-12-31. LCTX currently screens at market cap $213.6M.
CB currently screens at market cap $114.26B and trailing P/E 13.7. LCTX currently screens at market cap $213.6M.
Not investment advice. Open the CB and LCTX stock pages for the full models.
Not investment advice.